In order to participate in this study, you must be able to speak and read Dutch fluently.
The goal of this study is to evaluate how safe and effective the new drug CT1812 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug CT1812 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is administered orally.
Certain proteins (called amyloid beta oligomers) are believed to bind to brain cells in patients with AD, leading to memory problems and confusion. CT1812 is intended to enter the brain and block these proteins from attaching to brain cells. It is hoped that by blocking these proteins from binding to brain cells, patients with AD will experience improved symptoms.
You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 15 times, during approximately 9 months. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 6 hours, others 3.5 hours or shorter. The research takes place in Amsterdam, Den Bosch and Zwolle.
After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
If you decide to participate in the study, you sign a form and will start the study within several weeks.